About the Patient Derived Model Repository (PDMR)

PDMR Team/Core Facilities

Division of Cancer Treatment and Diagnosis (DCTD)

The Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI) takes prospective detection and treatment leads, facilitates their translation to clinical application, and expedites the initial and subsequent large-scale testing of new agents, biomarkers, imaging tests, and other therapeutic interventions (radiation, surgery, immunotherapy) in patients. Particularly, emphasis is put on the development of distinct molecular signatures for cancer, refined molecular assays, and state-of-the-art imaging techniques that will guide oncologic therapy in the future. Establishment of the NCI Patient-Derived Models Repository will provide new models with detailed molecular characterizations, carrying forward DCTD’s mission.

DCTD Overview

Biological Testing Branch (BTB)

The Biological Testing Branch (BTB) of the Developmental Therapeutics Program (DTP, DCTD), at NCI-Frederick, Frederick National Laboratory for Cancer Research (FNLCR) maintains the NCI Patient-Derived Models Repository (PDMR), develops and performs quality control on all new PDMR models (in vivo and in vitro), verifies the identity and viability of the cryopreserved samples, and determines minimal growth characteristics of the tumors and resulting cell lines.

BTB Homepage

Molecular Characterization Laboratory (MoCha)

he Molecular Characterization Laboratory (MoCha) is a CLIA-certified laboratory and part of the Cancer Diagnosis Program (CDP), DCTD, NCI operating at FNLCR. MoCha is responsible for performing all genetic sequencing and gene expression profiling of models in the PDMR. It has a full pathology group responsible for reviewing the histology of all PDX models created for the PDMR. MoCha has clearly defined SOPs and data analysis pipelines to ensure high quality characterization of all models.

MoCha Homepage

Cancer Imaging Program (CIP) and the Small Animal Imaging Program (SAIP)

The Cancer Imaging Program (CIP), DCTD, NCI collaborates with the PDMR through the application of imaging techniques to PDX-bearing mice. Much of this work is coordinated through the Small Animal Imaging Program (SAIP) at FNLCR. Imaging techniques such as 3D-ultrasound, MRI T2, and FDG PET/CT are applied to characterize PDX tumors as well as provide whole-mouse imaging to identify micro-mets and metastatic sites in PDX mice.

Contributing Institutions

The National Cancer Institute would like to thank the following National Institutes of Health Clinics and their patients for providing biological specimens for development of Patient-Derived Models

Developmental Therapeutics Clinic (DTC, DCTD, NCI)
Immune Deficiency - Cellular Therapy Program (CCR, NCI)
Neuro-Oncology Branch (CCR, NCI)
Pediatric Oncology Branch (CCR, NCI)
Surgical Oncology Program (CCR, NCI)
Women's Malignancies Branch (CCR, NCI)

The National Cancer Institute would like to thank the following institutions and their patients for providing biological specimens for development of Patient-Derived Models

Augusta University — Georgia Cancer Center
Baptist Health System/Mid-South Minority/Underserved NCORP
Cancer Research Consortium of West Michigan, NCORP
Cancer Research for the Ozarks, NCORP
Cancer Research of Kansas Consortium, NCORP
Children’s Cancer Therapy Development Institute, OR
Christiana Care Health Services NCORP
City of Hope Comprehensive Cancer Center
Columbia University Minority Underserved Site NCORP
Dana-Farber — Harvard Cancer Center, ETCTN LAO
Duke University — Duke Cancer Institute, ETCTN LAO
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Georgia Cares Minority/Underserved NCORP
H. Lee Moffitt Cancer Center & Research Institute
Heartland Cancer Research NCORP
Huntsman Cancer Institute, University of Utah
Indiana University, Simon Cancer Center
JHU Sidney Kimmel Comprehensive Cancer Center, ETCTN LAO
Johns Hopkins University School of Medicine — Legacy Gift Rapid Autopsy Program
Mayo Clinic Cancer Center, ETCTN LAO
Medical University of South Carolina, Hollings Cancer Center
Michigan Cancer Research Consortium NCORP
Montefiore Minority/Underserved NCORP
Nevada Cancer Research Foundation, NCORP
Northwest, NCORP
Ohio State University, OH
Roswell Park Cancer Institute
Stroger Hospital Cook County Minority/Underserved NCORP
University Health Network — Princess Margaret Phase I Consortium, NCORP
University of Alabama at Birmingham Comprehensive Cancer Center, U54
University of California Davis Comprehensive Cancer Center
University of Colorado Cancer Center
University of Connecticut Health Center — Waterbury Hospital
University of Iowa, Holden Comprehensive Cancer Center
University of Michigan Comprehensive Cancer Center
University of Nebraska, Rapid Autopsy Program
University of Texas MD Anderson Cancer Center, ETCTN LAO
University of Virginia Cancer Center
Vanderbilt-Ingram Cancer Center
Washington University School of Medicine, Siteman Cancer Center
Wisconsin, NCORP
Yale University Cancer Center, ETCTN LAO
Yale University Comprehensive Cancer Center

The National Cancer Institute would like to thank the following institutions and their patients for providing previously derived patient-derived xenograft material and cryo-preserved patient material to the Patient-Derived Models Repository

Baylor College of Medicine, TX
Children's Cancer Therapy Development Institute, OR
The Cholangiocarcinoma Foundation
Fred Hutchinson Cancer Research Center, WA
Huntsman Cancer Institute, UT
The Jackson Laboratory
Johns Hopkins University, School of Medicine, MD
Mayo Clinic Cancer Center, MN
MD Anderson Cancer Center, TX
PDXNet Consortium
Roswell Park Cancer Institute, NY
University of Alabama, Birmingham, AL
University of Arizona Cancer Center, AZ
University of California - Davis, CA
University of Colorado – Denver, CO
University of Texas Southwestern Medical Center, TX
Vanderbilt-Ingram Cancer Center, TN
Washington University - St. Louis, MO
West Virginia University, WV
The Wistar Institute, PA

Model Contributors

Coming Soon

Details on Contributing Institutions and Principal Investigators who have deposited models to the NCI PDMR that are currently available for researchers to request will be listed here along with a PI-designated contact in case there are additional questions about the Contributor models that are not available as part of the distribution material through the NCI PDMR.

The NCI PDMR database will also be revised soon to include a more streamlined view to specifically find models deposited to the NCI PDMR by Contributing Institutions and Principal Investigators. It should be noted for models to be deposited to the NCI PDMR the PIs need to:

provide a read copy of the patient informed consent confirming that sharing of the models and their associated data through a public database is allowed
provide detailed animal facility pathogen reports to ensure any deposited models meet the pathogen status outlined on our SOP document

PDMR Intramural Steering Committee

Toby Hecht, Ph.D., Deputy Director, Division of Cancer Treatment and Diagnosis (DCTD, NCI)
Melinda Hollingshead, DVM, Ph.D., Former Branch Chief, Biological Testing Branch (DTP, DCTD, NCI)
Chris Karlovich, Ph.D., Deputy Director, Molecular Characterization Laboratory (FNLCR, CDP, DCTD, NCI)
Kathleen Kelly, Ph.D., Chief, Laboratory of Genitourinary Cancer Pathogenesis (CCR, NCI)
Karlyne Reilly, Ph.D., Director, NCI Rare Tumor Initiative (POB, CCR, NCI)

Citing NCI Patient-Derived Models and Associated Data

To cite the PDMR as a reference, use a format similar to that shown below:

The NCI Patient-Derived Models Repository (PDMR), NCI-Frederick, Frederick National Laboratory for Cancer Research, Frederick, MD. URL — https://dctd.cancer.gov/drug-discovery-development/reagents-materials/pdmr

To cite models in the Methods section:

Use the full distribution lot name in the publication (e.g., 123456-001-R, 123456-001-R-J1-PDC), not an abbreviated form. In addition, the Contributor name, the lot# received, and the passage of material used for analysis should be cited. The name of the Contributor for a model is noted at the patient level in the PDMR database. Use a format as shown below:

Models developed by the PDMR:

Example: The PDX models 123456-001-R [Lot# AA1111] and 789123-001-R [Lot# BB2222] used in this study were developed by NCI PDMR.

Models developed by Contributing Institutions:

Example: The PDX models LG0123-001-R [Lot# AA111] and K12345-001-R [Lot# BB222] used in this study were developed by The Jackson Laboratory (Bar Harbor, ME) and are available from the NCI Patient Derived Models Repository (NCI PDMR; Frederick, MD; https://dctd-cms.cancer.gov/drug-discovery-development/reagents-materials/pdmr).
Example: The PDX model K12345-001-R [Lot# AA1111] used in this study was developed by MD Anderson Cancer Center (Houston, TX) and is available from the NCI Patient Derived Models Repository (NCI PDMR; Frederick, MD; https://dctd-cms.cancer.gov/drug-discovery-development/reagents-materials/pdmr).

Any modifications to the distributed model should be identified (e.g., transfection, CRISPR, etc.).

Sequence files downloaded for use in analysis should be referenced including the version# listed in the file name as different pipeline versions may result in different interpretations of the data (e.g., v1.2, v1.3, v2.0.1.51.0).

Please note:

This README file lists previously posted sequence files that should be removed from any subsequent analysis.

Contact Us

Please send e-mail to NCI_PDM_Repository@mail.nih.gov for any of the following:

Questions or Comments
To Contribute Patient Material
To Contribute Previously Derived PDX Models

* Initial requirements for discussion of depositing models will include a blank copy of the informed consent document used to generate models and animal facility pathogen status reports (including Corynebacterium bovis and Mouse Kidney Parvovirus).